Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Unknown × lanreotide × Clear all

Phase

Phase 2 2 Phase EARLY_PHASE1 1 Phase 4 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

fludarabine 15 Cyclophosphamide 14 Positron Emission Tomography Computed Tomography 4 Metformin 4 Gemcitabine 4 68Ga-pentixafor 4 Oncolytic Virotherapy 3 Melphalan 3 Immunotherapy, Adoptive 3 Cholestanetriol 26-Monooxygenase 3 Bevacizumab 3 toripalimab 2 pembrolizumab 2 lenvatinib 2 gallium Ga 68 dotatate 2 gallium 68 PSMA-11 2 fludarabine phosphate 2 alpha-Synuclein 2 Temozolomide 2 Radiotherapy 2 Radiosurgery 2 Radiation 2 Progesterone 2 Pemetrexed 2 Paclitaxel 2 Nivolumab 2 Neoadjuvant Therapy 2 Magnetic Resonance Spectroscopy 2 Influenza Vaccines 2 Fluorodeoxyglucose F18 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02823691 2021-06-07

MetNET-2

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase EARLY_PHASE1 Unknown

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡